These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 36707424)

  • 1. Using EGFR amplification to stratify recurrent glioblastoma treated with immune checkpoint inhibitors.
    Friedman JS; Jun T; Rashidipour O; Huang KL; Ellis E; Kadaba P; Belani P; Nael K; Tsankova NM; Sebra R; Hormigo A
    Cancer Immunol Immunother; 2023 Jun; 72(6):1893-1901. PubMed ID: 36707424
    [TBL] [Abstract][Full Text] [Related]  

  • 2. EGFR amplification and classical subtype are associated with a poor response to bevacizumab in recurrent glioblastoma.
    Hovinga KE; McCrea HJ; Brennan C; Huse J; Zheng J; Esquenazi Y; Panageas KS; Tabar V
    J Neurooncol; 2019 Apr; 142(2):337-345. PubMed ID: 30680510
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma: The CheckMate 143 Phase 3 Randomized Clinical Trial.
    Reardon DA; Brandes AA; Omuro A; Mulholland P; Lim M; Wick A; Baehring J; Ahluwalia MS; Roth P; Bähr O; Phuphanich S; Sepulveda JM; De Souza P; Sahebjam S; Carleton M; Tatsuoka K; Taitt C; Zwirtes R; Sampson J; Weller M
    JAMA Oncol; 2020 Jul; 6(7):1003-1010. PubMed ID: 32437507
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical characteristics of patients treated with immune checkpoint inhibitors in EGFR-mutant non-small cell lung cancer: CS-Lung-003 prospective observational registry study.
    Kuribayashi T; Ohashi K; Nishii K; Ninomiya K; Tsubata Y; Ishikawa N; Kodani M; Kanaji N; Yamasaki M; Fujitaka K; Kuyama S; Takigawa N; Fujimoto N; Kubota T; Inoue M; Fujiwara K; Harita S; Takata I; Takada K; Okawa S; Kiura K; Hotta K
    J Cancer Res Clin Oncol; 2024 Feb; 150(2):89. PubMed ID: 38347279
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of osimertinib plus bevacizumab in glioblastoma patients with simultaneous EGFR amplification and EGFRvIII mutation.
    Cardona AF; Jaramillo-Velásquez D; Ruiz-Patiño A; Polo C; Jiménez E; Hakim F; Gómez D; Ramón JF; Cifuentes H; Mejía JA; Salguero F; Ordoñez C; Muñoz Á; Bermúdez S; Useche N; Pineda D; Ricaurte L; Zatarain-Barrón ZL; Rodríguez J; Avila J; Rojas L; Jaller E; Sotelo C; Garcia-Robledo JE; Santoyo N; Rolfo C; Rosell R; Arrieta O
    J Neurooncol; 2021 Sep; 154(3):353-364. PubMed ID: 34498213
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
    Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-epidermal growth factor receptor therapy for glioblastoma in adults.
    Lee A; Arasaratnam M; Chan DLH; Khasraw M; Howell VM; Wheeler H
    Cochrane Database Syst Rev; 2020 May; 5(5):CD013238. PubMed ID: 32395825
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
    Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
    Cochrane Database Syst Rev; 2021 Apr; 4(4):CD013257. PubMed ID: 33930176
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PD-1/PD-L1 combined with LAG3 is associated with clinical activity of immune checkpoint inhibitors in metastatic primary pulmonary lymphoepithelioma-like carcinoma.
    Zhong YM; Yin K; Chen Y; Xie Z; Lv ZY; Yang JJ; Yang XN; Zhou Q; Wang BC; Zhong WZ; Gao LL; Zhou WB; Chen J; Tu HY; Liao RQ; Zhang DK; Zhang SL; Lu DX; Zheng HB; Zhang HH; Wu YL; Zhang XC
    Front Immunol; 2022; 13():951817. PubMed ID: 36263036
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diffusion MRI is an early biomarker of overall survival benefit in IDH wild-type recurrent glioblastoma treated with immune checkpoint inhibitors.
    Hagiwara A; Oughourlian TC; Cho NS; Schlossman J; Wang C; Yao J; Raymond C; Everson R; Patel K; Mareninov S; Rodriguez FJ; Salamon N; Pope WB; Nghiemphu PL; Liau LM; Prins RM; Cloughesy TF; Ellingson BM
    Neuro Oncol; 2022 Jun; 24(6):1020-1028. PubMed ID: 34865129
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Concomitant Proton Pump Inhibitor Use With Pembrolizumab Monotherapy vs Immune Checkpoint Inhibitor Plus Chemotherapy in Patients With Non-Small Cell Lung Cancer.
    Kawachi H; Yamada T; Tamiya M; Negi Y; Goto Y; Nakao A; Shiotsu S; Tanimura K; Takeda T; Okada A; Harada T; Date K; Chihara Y; Hasegawa I; Tamiya N; Ishida M; Katayama Y; Morimoto K; Iwasaku M; Tokuda S; Kijima T; Takayama K
    JAMA Netw Open; 2023 Jul; 6(7):e2322915. PubMed ID: 37432682
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical outcomes of immune checkpoint inhibitors to treat non-small cell lung cancer patients harboring epidermal growth factor receptor mutations.
    Si J; Hao Y; Wei J; Xiang J; Xu C; Shen Q; Song Z
    BMC Pulm Med; 2023 May; 23(1):158. PubMed ID: 37147602
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor immune microenvironment and nivolumab efficacy in EGFR mutation-positive non-small-cell lung cancer based on T790M status after disease progression during EGFR-TKI treatment.
    Haratani K; Hayashi H; Tanaka T; Kaneda H; Togashi Y; Sakai K; Hayashi K; Tomida S; Chiba Y; Yonesaka K; Nonagase Y; Takahama T; Tanizaki J; Tanaka K; Yoshida T; Tanimura K; Takeda M; Yoshioka H; Ishida T; Mitsudomi T; Nishio K; Nakagawa K
    Ann Oncol; 2017 Jul; 28(7):1532-1539. PubMed ID: 28407039
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Resistance to immune checkpoint inhibitors in advanced lung cancer: Clinical characteristics, potential prognostic factors and next strategy.
    Zhou J; Lu X; Zhu H; Ding N; Zhang Y; Xu X; Gao L; Zhou J; Song Y; Hu J
    Front Immunol; 2023; 14():1089026. PubMed ID: 36776868
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Congress of neurological surgeons systematic review and evidence-based guidelines update on the role of neuropathology in the management of progressive glioblastoma in adults.
    Goodman AL; Velázquez Vega JE; Glenn C; Olson JJ
    J Neurooncol; 2022 Jun; 158(2):179-224. PubMed ID: 35648306
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Integration of comprehensive genomic profiling, tumor mutational burden, and PD-L1 expression to identify novel biomarkers of immunotherapy in non-small cell lung cancer.
    Shi Y; Lei Y; Liu L; Zhang S; Wang W; Zhao J; Zhao S; Dong X; Yao M; Wang K; Zhou Q
    Cancer Med; 2021 Apr; 10(7):2216-2231. PubMed ID: 33655698
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment with immune checkpoint inhibitors after EGFR-TKIs in EGFR-mutated lung cancer.
    Ito T; Nagashima H; Akiyama M; Utsumi Y; Sato H; Chiba S; Sugai M; Ube K; Mori Y; Watanabe K; Fukuhara T; Maemondo M
    Thorac Cancer; 2022 Feb; 13(3):386-393. PubMed ID: 34904383
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A multicenter, phase II trial of GC1118, a novel anti-EGFR antibody, for recurrent glioblastoma patients with EGFR amplification.
    Choi SW; Jung HA; Cho HJ; Kim TM; Park CK; Nam DH; Lee SH
    Cancer Med; 2023 Aug; 12(15):15788-15796. PubMed ID: 37537946
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictive value of p53 and AXL immunostaining for the efficacy of immune checkpoint inhibitor-based therapy after osimertinib treatment in patients with epidermal growth factor-mutant non-small cell lung cancer.
    Morimoto K; Yamada T; Sawada R; Azuma K; Goto Y; Harada T; Shiotsu S; Tamiya N; Chihara Y; Takeda T; Hiranuma O; Hasegawa I; Tanaka S; Yoshimura A; Iwasaku M; Tokuda S; Kim YH; Takayama K
    Cancer Immunol Immunother; 2023 Jun; 72(6):1699-1707. PubMed ID: 36617602
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment with pembrolizumab in programmed death ligand 1-positive recurrent glioblastoma: Results from the multicohort phase 1 KEYNOTE-028 trial.
    Reardon DA; Kim TM; Frenel JS; Simonelli M; Lopez J; Subramaniam DS; Siu LL; Wang H; Krishnan S; Stein K; Massard C
    Cancer; 2021 May; 127(10):1620-1629. PubMed ID: 33496357
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.